KR20210033490A - 파라튜버큘로시스에 대한 면역원성 조성물 - Google Patents

파라튜버큘로시스에 대한 면역원성 조성물 Download PDF

Info

Publication number
KR20210033490A
KR20210033490A KR1020217004231A KR20217004231A KR20210033490A KR 20210033490 A KR20210033490 A KR 20210033490A KR 1020217004231 A KR1020217004231 A KR 1020217004231A KR 20217004231 A KR20217004231 A KR 20217004231A KR 20210033490 A KR20210033490 A KR 20210033490A
Authority
KR
South Korea
Prior art keywords
ala
polypeptide
leu
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217004231A
Other languages
English (en)
Korean (ko)
Inventor
존 허몬-테일러
Original Assignee
에이치에이브이 백신즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이치에이브이 백신즈 리미티드 filed Critical 에이치에이브이 백신즈 리미티드
Publication of KR20210033490A publication Critical patent/KR20210033490A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217004231A 2018-07-11 2019-07-10 파라튜버큘로시스에 대한 면역원성 조성물 Ceased KR20210033490A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1811382.9 2018-07-11
GBGB1811382.9A GB201811382D0 (en) 2018-07-11 2018-07-11 Vaccine
PCT/GB2019/051933 WO2020012177A1 (en) 2018-07-11 2019-07-10 Immunogenic composition for paratuberculosis

Publications (1)

Publication Number Publication Date
KR20210033490A true KR20210033490A (ko) 2021-03-26

Family

ID=63273113

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217004231A Ceased KR20210033490A (ko) 2018-07-11 2019-07-10 파라튜버큘로시스에 대한 면역원성 조성물

Country Status (14)

Country Link
US (2) US12186382B2 (enExample)
EP (1) EP3820507A1 (enExample)
JP (2) JP2021524485A (enExample)
KR (1) KR20210033490A (enExample)
CN (1) CN113329765A (enExample)
AU (1) AU2019301899A1 (enExample)
BR (1) BR112021000312A2 (enExample)
CA (1) CA3105763A1 (enExample)
GB (1) GB201811382D0 (enExample)
IL (1) IL280070B2 (enExample)
MA (1) MA53131A (enExample)
MX (1) MX2020013924A (enExample)
SG (1) SG11202100120TA (enExample)
WO (1) WO2020012177A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
WO2026041756A1 (en) 2024-08-21 2026-02-26 Hav Vaccines Limited Treatment of crohn's disease by mycobacterium avium subsp. paratuberculosis agent

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225324A (en) 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JPH07505283A (ja) 1992-03-20 1995-06-15 ベイラー・カレッジ・オブ・メディシン Ｄｎａトランスポーター系および使用方法
AU682308C (en) 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
ATE466876T1 (de) 2005-08-09 2010-05-15 Hav Vaccines Ltd Immunogene konstrukte
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN102596236B (zh) 2009-07-30 2015-06-24 辉瑞疫苗有限责任公司 抗原性Tau肽及其用途
EP2710151A4 (en) 2011-05-19 2014-12-10 Univ Central Florida Res Found MICROBEND DETECTION BY HYBRIDIZATION OF MAGNETIC RELAXATION NANOSENSORS
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
JP2016513078A (ja) * 2013-01-28 2016-05-12 ダンマルクス テクニスケ ウニベルシテット 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン
GB201700487D0 (en) * 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic

Also Published As

Publication number Publication date
US20210338791A1 (en) 2021-11-04
IL280070A (en) 2021-03-01
JP2021524485A (ja) 2021-09-13
IL280070B1 (en) 2023-12-01
US20250152691A1 (en) 2025-05-15
IL280070B2 (en) 2024-04-01
MX2020013924A (es) 2021-03-02
CN113329765A (zh) 2021-08-31
CA3105763A1 (en) 2020-01-16
MA53131A (fr) 2021-05-19
SG11202100120TA (en) 2021-02-25
JP2024153666A (ja) 2024-10-29
GB201811382D0 (en) 2018-08-29
EP3820507A1 (en) 2021-05-19
WO2020012177A1 (en) 2020-01-16
AU2019301899A1 (en) 2021-01-14
BR112021000312A2 (pt) 2021-04-13
US12186382B2 (en) 2025-01-07

Similar Documents

Publication Publication Date Title
US8697856B2 (en) Plasmodium vivax hybrid circumsporozoite protein and vaccine
US20250152691A1 (en) Immunogenic composition for paratuberculosis
CA2884918C (en) Salmonid alphavirus and uses thereof
JP2001527393A (ja) ヘリコバクターゲノム中の新規ヘリコバクターポリペプチドをコードするポリヌクレオチドの同定
JP2004041219A (ja) アクチノバチルス・プレウロニウモニアからのタンパク質
JP2016513078A (ja) 一段階または多段階のトリ型結核菌亜種副結核症サブユニット・ワクチン
US8147850B2 (en) Immunogenic constructs
EP0854919A1 (en) Melanoma-associated protein
US20210205430A1 (en) Virb10 for vaccination against gram negative bacteria
KR20190082229A (ko) 스타필로코커스 감염에 대한 백신 구성체 및 이의 용도
JP2003521881A (ja) ローソニア由来の遺伝子及び関連ＯｍｐＨポリペプチド、ぺプチド及びタンパク質並びにそれらの使用
WO1996040926A2 (en) Detection of cryptosporidium parvum
JP2000510339A (ja) インビボで発現されるＢ．ｂｕｒｇｄｏｒｆｅｒｉポリペプチド
Bull et al. A Novel Multi-Antigen Virally Vectored Vaccine against Mycobacterium avium
JP2007502602A (ja) 前立腺癌の治療用の前立腺特異的抗原をコードするポックスウィルスベクター

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210210

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220711

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250206

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250411

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D